Matinas BioPharma
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
March 27, 2024 16:05 ET | Matinas BioPharma Holdings, Inc.
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded...
Matinas' Positivein vivo Safety Data with its Oral LNC-Docetaxel Formulation
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
March 25, 2024 08:00 ET | Matinas BioPharma Holdings, Inc.
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel ...
Matinas BioPharma
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
March 22, 2024 09:15 ET | Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies...
Matinas BioPharma
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
March 22, 2024 06:30 ET | Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies...
Matinas BioPharma
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
February 26, 2024 08:00 ET | Matinas BioPharma Holdings, Inc.
A total of 19 patients with serious/life-threatening invasive fungal infections have been enrolled, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptococcosis, and endemic mycoses...
Matinas BioPharma
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
February 20, 2024 07:30 ET | Matinas BioPharma Holdings, Inc.
ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options ...
Matinas BioPharma
Matinas BioPharma to Present at Biotech Showcase 2024
January 03, 2024 07:00 ET | Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small...
Matinas BioPharma
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
December 27, 2023 07:30 ET | Matinas BioPharma Holdings, Inc.
In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement in disease activity scores In an acute...
Matinas BioPharma
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
December 21, 2023 07:30 ET | Matinas BioPharma Holdings, Inc.
Written Preliminary Comments on the Phase 3 Registration Trial for MAT2203 Move Company Closer to Full Alignment with FDA Matinas to Meet with FDA Early in the First Quarter of 2024 to Finalize Phase...
Matinas BioPharma
Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 08, 2023 16:05 ET | Matinas BioPharma Holdings, Inc.
FDA feedback on MAT2203 Phase 3 program supports a patient population in invasive aspergillosis with limited treatment options, acknowledges potential for LPAD pathway; composite superiority endpoint...